Auto-reactive B cells in MuSK myasthenia gravis
نویسندگان
چکیده
منابع مشابه
Myasthenia gravis patients with anti-MuSK antibodies.
In myasthenia gravis (MG) patients without detectable anti-acetylcholine receptor (anti-AChR) antibody, referred to as seronegative myasthenia gravis patients, there is a variable proportion of patients with antibodies against the muscle-specific kinase (MuSK). MuSK antibodies were found in 8 (29.6%) of our 27 patients with generalized MG without anti-AChR antibodies. All these patients were fe...
متن کاملIncreased complement consumption in MuSK-antibody-positive myasthenia gravis patients.
OBJECTIVE To investigate the activation of different complement pathways in myasthenia gravis (MG) subtypes. SUBJECTS AND METHODS Levels of complement breakdown products for different complement pathways were measured using ELISA in sera of acetylcholine receptor antibody (AChR-Ab)-positive (n = 21), muscle-specific receptor tyrosine kinase (MuSK)-Ab-positive (n = 23) and seronegative general...
متن کاملRepetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
BACKGROUND AND PURPOSE Responses to repetitive nerve stimulation (RNS) in patients with muscle-specific tyrosine kinase (MuSK) antibody (Ab)-positive myasthenia gravis (MG) vary depending on the muscles tested. We analyzed the RNS responses of limb and facial muscles in MuSK-Ab-positive and acetylcholine receptor (AChR)-Ab-negative MG (MuSK MG) and MuSK-Ab-negative and AChR-Ab-negative [double-...
متن کاملAnti-Musk Positive Myasthenia Gravis and Three Semiological Cardinal Signs
Myasthenia gravis (MG) is a relatively uncommon disorder with an annual incidence of approximately 7 to 9 new cases per million. The prevalence is about 70 to 165 per million. The prevalence of the disease has been increasing over the past five decades. This is thought to be due to better recognition of the condition, aging of the population, and the longer life span of affected patients. MG ca...
متن کاملProlonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
Rituximab (RTX) therapy is used increasingly to manage myasthenia gravis (MG) patients, and case series have shown particular benefit for those MG patients who have antibodies to muscle-specific kinase (MuSK-MG). We report a MuSK-MG patient with persistent and severe Bcell depletion 3 years after receiving RTX. A 62-year-old woman developed ptosis, bulbar symptoms, and weight loss in 2000. In 2...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuroimmunology and Neuroinflammation
سال: 2016
ISSN: 2349-6142,2347-8659
DOI: 10.20517/2347-8659.2016.33